? San Diego-based Equillium has nabbed an orphan drug designation for EQ001 on the verge of beginning a Phase Ib/II for the immuno-inflammatory drug. Also known as itolizumab, the drug was in-licensed from India’s Biocon, which sells it in the country as a psoriasis treatment. Equillium $EQ, however, is focusing its US clinical work on the prevention and treatment of acute graft-versus-host disease — a strategy that has allowed it to skip financing rounds and jump str
Industry News
Lilly, Incyte’s baricitinib wins fast-track status for hard-to-treat lupus; Synthorx hammers out $150M+ IPO
? Rheumatoid arthritis drug Olumiant — approved for a narrower-than-expected patient population earlier this year to the dismay of its manufacturer Eli Lilly $LLY and Incyte $INCY which had blockbuster dreams for the drug — may be worth its weight in g… […]
Industry News
Lilly, Incyte’s baricitinib wins fast-track status for hard-to-treat lupus; Synthorx hammers out $150M+ IPO
? Rheumatoid arthritis drug Olumiant — approved for a narrower-than-expected patient population earlier this year to the dismay of its manufacturer Eli Lilly $LLY and Incyte $INCY which had blockbuster dreams for the drug — may be worth its weight in g… […]
News
Rubius cites some preclinical progress; Xencor scores deal with Astellas; Eidos to restate quarterly filings
? Rubius Therapeutics $RUBY has posted some positive — though preclinical — study results on its red blood cell tech, saying they were able to track a desired immune response using their drugs.The therapies are designed to increase the flow of T cells … […]
